The US company Moderna announced on Wednesday that it has begun clinical trials for a booster dose of a vaccine specifically designed to combat the Omicron mutation of the coronavirus. [BR][BR]The trials will be conducted in 600 adults, half of whom have already received two doses of Moderna's vaccine at least six months ago, and the other half have received two doses plus the booster dose already approved. [THE BOOSTER DOSE THAT IS BEING PREPARED SPECIFICALLY TARGETS OMICRON, SO IT WILL BE EVALUATED AS BOTH A THIRD AND FOURTH DOSE.
(CNA)
CNA - French News Agency
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
